OncoZenge Appoints LINK Medical to Execute Phase 3 Feasibility Study in Europe

OncoZenge AB (publ) ("OncoZenge" or "the Company") today announces that LINK Medical has been engaged to conduct a feasibility study in Europe for the Company’s planned Phase 3 study for European approval of BupiZenge™.

OncoZenge is planning a multi-country Phase 3 study for the approval of BupiZenge™ in Europe. The scope of the Phase 3 study has been updated in recent weeks in close collaboration with the Company’s licensing partner, Molteni Farmaceutici. As part of the planning and to optimize lead-times, the Company has engaged LINK Medical to perform a feasibility study for the European part of the study.

The study aims to confirm the availability of suitable sites in Europe, with a focus on Germany, Denmark, Norway, and Sweden. The study will also provide important validation of the expected patient recruitment rate and, consequently, the overall timeline.

"We are very pleased to collaborate with OncoZenge in this feasibility study. At LINK Medical, we specialize in guiding Nordic biotech companies through the complex clinical landscape in Europe. This partnership reflects our commitment to providing practical expertise, local insights, and seamless execution to help our clients succeed in every development phase." - Anders Göransson, CEO LINK Medical.

“The availability and selection of study sites in Europe is a critical issue that lies on the critical path of the timeline for our Phase 3 program. Obtaining decision-making data on this during the summer will thus save valuable time later. LINK Medical has made a very positive impression, and we look forward to a successful collaboration towards our goal of initiating the full Phase 3 project for BupiZenge,” says Stian Kildal, CEO of OncoZenge.
 

BupiZenge™ – Potential to be the leading treatment for oral pain.